WASHINGTON - A federal vaccine advisory committee said Wednesday it wanted more data before deciding whether to resume use of Johnson & Johnson's coronavirus vaccine, leaving in place a pause that federal officials had recommended because of a rare and severe type of blood clot identified so far among six of the 7.5 million people who received the shot.